Bristol-Myers Squibb BMY Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $9.57B-6.2% | $10.21B-35.1% | $15.73B+24.8% | $12.6B+15.9% | $10.88B+5.1% | ||
| $912M+96.6% | $464M-40.2% | $776M-22.7% | $1B+10.7% | $907M+76.8% | ||
| $9.37B-17.9% | $11.41B-0.1% | $11.42B+0.1% | $11.42B+5.7% | $10.8B+0.5% | ||
| $2.76B+2.5% | $2.69B-2.5% | $2.76B+0.8% | $2.74B+2.7% | $2.67B+4.3% | ||
| $27.21B-7.4% | $29.39B-17.5% | $35.63B+7.2% | $33.22B+7.9% | $30.78B+3.4% | ||
| $7.66B+1.5% | $7.54B+2.6% | $7.35B-0.3% | $7.37B+2.2% | $7.21B+1.1% | ||
| $21.74B-0.1% | $21.75B0.0% | $21.75B-0.1% | $21.78B+0.2% | $21.74B+0.1% | ||
| $161M+141% | -$392M-108% | $4.96B+6.8% | $4.65B+16.3% | $4B-5.6% | ||
| $86.48B-4.0% | $90.04B-7.1% | $96.89B+2.3% | $94.68B+2.4% | $92.43B-0.2% | ||
| $4.23B+18.4% | $3.58B-16.6% | $4.29B-21.0% | $5.43B+35.6% | $4B+11.1% | ||
| $2.31B+2.1% | $2.26B-49.9% | $4.51B-4.4% | $4.72B+32.7% | $3.55B+73.7% | ||
| $199M-1.5% | $202M-5.6% | $214M+10.3% | $194M+12.8% | $172M-5.0% | ||
| $2.31B+2.1% | $2.26B-49.9% | $4.51B-4.4% | $4.72B+32.7% | $3.55B+73.7% | ||
| $187M+158% | -$324M-137% | $887M+243% | -$621M-1,250% | $54M— | ||
| $19.16B-18.2% | $23.42B-16.8% | $28.14B+2.2% | $27.53B+14.4% | $24.07B+1.2% | ||
| $42.15B-1.6% | $42.85B-3.6% | $44.47B0.0% | $44.47B-3.7% | $46.16B-3.0% | ||
| $4.85B-3.8% | $5.04B-7.6% | $5.46B+10.5% | $4.94B+10.4% | $4.48B+0.2% | ||
| $66.37B-7.2% | $71.53B-8.6% | $78.29B+1.4% | $77.19B+2.9% | $74.98B-1.6% | ||
| $292M0.0% | $292M0.0% | $292M0.0% | $292M0.0% | $292M0.0% | ||
| $46.37B0.0% | $46.39B+0.3% | $46.27B+0.3% | $46.13B+0.3% | $46.01B0.0% | ||
| $18.29B+8.2% | $16.9B-1.2% | $17.09B+5.8% | $16.15B+0.3% | $16.11B+8.0% | ||
| -$1.37B+10.1% | -$1.52B-0.7% | -$1.51B+2.6% | -$1.55B-9.1% | -$1.42B-15.0% | ||
| $43.52B-0.1% | $43.58B0.0% | $43.59B0.0% | $43.59B0.0% | $43.6B-0.1% | ||
| $20.07B+8.6% | $18.47B-0.4% | $18.55B+6.4% | $17.44B+0.3% | $17.39B+6.5% | ||
| $86.48B-4.0% | $90.04B-7.1% | $96.89B+2.3% | $94.68B+2.4% | $92.43B-0.2% | ||
| $912M+96.6% | $464M-40.2% | $776M-22.7% | $1B+10.7% | $907M+76.8% | ||
| $4.6B-0.3% | $4.61B-6.8% | $4.95B-9.5% | $5.47B-1.2% | $5.53B-1.5% | ||
| $6.08B-6.1% | $6.47B+2.2% | $6.33B+6.7% | $5.94B+1.2% | $5.87B-3.9% | ||
| $366M-7.6% | $396M-2.5% | $406M+17.3% | $346M+0.6% | $344M+7.5% | ||
| $5.18B-3.8% | $5.38B+8.4% | $4.96B+6.8% | $4.65B+16.3% | $4B-5.6% | ||
| $18.24B-4.5% | $19.1B-6.7% | $20.47B-4.3% | $21.38B-4.9% | $22.49B-3.5% | ||
| $6.08B-6.1% | $6.47B+2.2% | $6.33B+6.7% | $5.94B+1.2% | $5.87B-3.9% | ||
| $6.08B-6.1% | $6.47B+2.2% | $6.33B+6.7% | $5.94B+1.2% | $5.87B-3.9% | ||
| $12.62B-28.2% | $17.58B-9.1% | $19.34B+11.2% | $17.39B+5.3% | $16.51B-8.9% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $2.31B+2.1% | $2.26B-49.9% | $4.51B-4.4% | $4.72B+32.7% | $3.55B+73.7% | ||
| $211M-5.0% | $222M-1.3% | $225M-8.9% | $247M-10.5% | $276M-25.2% | ||
| $34M+3.0% | $33M-31.3% | $48M-11.1% | $54M-8.5% | $59M+11.3% | ||
| —— | 2.5K— | —— | —— | —— | ||
| —— | 2.5K— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Bristol-Myers Squibb's total assets?
- Bristol-Myers Squibb (BMY) holds $86.5B in total assets, down 6.4% year over year.
- How much debt does Bristol-Myers Squibb have?
- Bristol-Myers Squibb carries $44.7B in total debt against $20.1B of shareholders' equity, a debt-to-equity ratio of 2.23.
- How much cash does Bristol-Myers Squibb have?
- Bristol-Myers Squibb holds $9.6B in cash and equivalents.
- Can Bristol-Myers Squibb cover its short-term obligations?
- Its current ratio is 1.42 — current assets exceed current liabilities.
- Where does Bristol-Myers Squibb's balance sheet data come from?
- Every line is extracted from Bristol-Myers Squibb's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
